This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Oct 28;385(18):1725-1726.

doi: 10.1056/NEJMc2106424.

Pegcetacoplan versus Eculizumab in PNH. Reply

Peter Hillmen¹, Antonio M Risitano², Régis Peffault de Latour³

Affiliations

Affiliations

¹ St James's University Hospital, Leeds, United Kingdom p.hillmen@leeds.ac.uk.
² AORN San Giuseppe Moscati, Avellino, Italy.
³ Saint-Louis Hospital, Paris, France.

PMID: 34706185
DOI: 10.1056/NEJMc2106424

Comment

Pegcetacoplan versus Eculizumab in PNH. Reply

Peter Hillmen et al. N Engl J Med. 2021.

. 2021 Oct 28;385(18):1725-1726.

doi: 10.1056/NEJMc2106424.

Authors

Peter Hillmen¹, Antonio M Risitano², Régis Peffault de Latour³

Affiliations

¹ St James's University Hospital, Leeds, United Kingdom p.hillmen@leeds.ac.uk.
² AORN San Giuseppe Moscati, Avellino, Italy.
³ Saint-Louis Hospital, Paris, France.

PMID: 34706185
DOI: 10.1056/NEJMc2106424

No abstract available

PubMed Disclaimer

Comment on

Pegcetacoplan versus Eculizumab in PNH.
Ueda Y, Takamori H, Nishimura JI. Ueda Y, et al. N Engl J Med. 2021 Oct 28;385(18):1723-1724. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706182 No abstract available.
Pegcetacoplan versus Eculizumab in PNH.
Kulasekararaj AG, Gandhi S, Brodsky RA. Kulasekararaj AG, et al. N Engl J Med. 2021 Oct 28;385(18):1724-1725. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706183 No abstract available.
Pegcetacoplan versus Eculizumab in PNH.
Gurnari C, Pagliuca S, Maciejewski JP. Gurnari C, et al. N Engl J Med. 2021 Oct 28;385(18):1725. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706184 No abstract available.

Similar articles

Pegcetacoplan versus Eculizumab in PNH.
Gurnari C, Pagliuca S, Maciejewski JP. Gurnari C, et al. N Engl J Med. 2021 Oct 28;385(18):1725. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706184 No abstract available.
Pegcetacoplan versus Eculizumab in PNH.
Kulasekararaj AG, Gandhi S, Brodsky RA. Kulasekararaj AG, et al. N Engl J Med. 2021 Oct 28;385(18):1724-1725. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706183 No abstract available.
Pegcetacoplan versus Eculizumab in PNH.
Ueda Y, Takamori H, Nishimura JI. Ueda Y, et al. N Engl J Med. 2021 Oct 28;385(18):1723-1724. doi: 10.1056/NEJMc2106424. N Engl J Med. 2021. PMID: 34706182 No abstract available.
Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.
Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K, Morita Y, Nishiwaki K, Ninomiya H, Gotoh A, Imashuku S, Urabe A, Shichishima T, Nishimura J, Kanakura Y. Miyasaka N, et al. Int J Hematol. 2016 Jun;103(6):703-12. doi: 10.1007/s12185-016-1946-x. Epub 2016 Feb 8. Int J Hematol. 2016. PMID: 26857155 Review.
C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R, Sica M. Notaro R, et al. Semin Hematol. 2018 Jul;55(3):130-135. doi: 10.1053/j.seminhematol.2018.05.014. Epub 2018 Jun 5. Semin Hematol. 2018. PMID: 30032749 Review.

See all similar articles

Cited by

Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval.
Horneff R, Czech B, Yeh M, Surova E. Horneff R, et al. Int J Mol Sci. 2024 Aug 9;25(16):8698. doi: 10.3390/ijms25168698. Int J Mol Sci. 2024. PMID: 39201383 Free PMC article. Review.
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Patriquin CJ, Bogdanovic A, Griffin M, Kelly RJ, Maciejewski JP, Mulherin B, Peffault de Latour R, Röth A, Selvaratnam V, Szer J, Al-Adhami M, Horneff R, Tan L, Yeh M, Panse J. Patriquin CJ, et al. Adv Ther. 2024 May;41(5):2050-2069. doi: 10.1007/s12325-024-02827-8. Epub 2024 Apr 4. Adv Ther. 2024. PMID: 38573482 Free PMC article.
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.
Peffault de Latour R, Griffin M, Kelly RJ, Szer J, de Castro C, Horneff R, Tan L, Yeh M, Panse J. Peffault de Latour R, et al. Blood Adv. 2024 Jun 11;8(11):2718-2725. doi: 10.1182/bloodadvances.2024012672. Blood Adv. 2024. PMID: 38593241 Free PMC article. Clinical Trial.
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Risitano AM, Frieri C, Urciuoli E, Marano L. Risitano AM, et al. Immunol Rev. 2023 Jan;313(1):262-278. doi: 10.1111/imr.13137. Epub 2022 Sep 15. Immunol Rev. 2023. PMID: 36110036 Free PMC article. Review.
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH.
Griffin M, Kelly RJ, Panse J, de Castro C, Szer J, Horneff R, Tan L, Yeh M, Peffault de Latour R. Griffin M, et al. Blood Adv. 2024 Apr 9;8(7):1776-1786. doi: 10.1182/bloodadvances.2023011691. Blood Adv. 2024. PMID: 38315872 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.